Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CMX 2043

Next Previous
Drug Profile

CMX 2043

Alternative Names: CMX-2043

Latest Information Update: 01 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ischemix
  • Class Cytoprotectives; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Proto-oncogene protein c-akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Reperfusion injury
  • Phase I Traumatic brain injuries

Most Recent Events

  • 25 Aug 2023 Ischemix plans a phase II trial for Traumatic brain injuries
  • 25 Aug 2023 Ischemix plans a meeting with US FDA in early Q1 2024
  • 25 Aug 2023 Adverse events and pharmacokinetics data from a phase I trial in Traumatic brain injuries released by Ischemix

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top